SCHEMBL6326795

SCHEMBL6326795

COc1ccc2c(c1)C(CCc1ccc(F)cc1)=NCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
GLA P06280 1/20 0.54
RCE1 Q9Y256 1/20 0.54
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
HSD17B10 Q99714 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAPK14 Q16539 2/20 0.41
CYP19A1 P11511 1/20 0.40
CYP24A1 Q07973 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
DRD2 P14416 1/20 0.39
DRD3 P35462 1/20 0.39
RAD52 P43351 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375509 0.80 ALDH1A1 (0.51) KDM4EGLARCE1ALDH1A1LMNA
SCHEMBL8486596 0.78 KDM4E (0.72) KDM4EGLARCE1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL3450797 0.76 KDM4E (0.51) KDM4EGLARCE1ALDH1A1LMNA
SCHEMBL6321890 0.73 KDM4E (0.46) KDM4EGLARCE1HSD17B10CYP1A2
SCHEMBL3452769 0.73 KDM4E (0.45) KDM4EALDH1A1LMNADRD2DRD3
SCHEMBL8025519 0.72 KDM4E (0.79) KDM4EGLARCE1ALDH1A1LMNA
SCHEMBL24528920 0.72 KDM4E (0.59) KDM4EGLARCE1ALDH1A1LMNA
SCHEMBL7474018 0.71 KDM4E (0.60) KDM4EALDH1A1MAOBMEN1KMT2A
SCHEMBL990162 0.71 KDM4E (0.72) KDM4EGLARCE1ALDH1A1LMNA
SCHEMBL1010356 0.70 MAOA (0.60) KDM4EGLAALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908931-B2 Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-21 US disclosed
US-20040235891-A1 Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists BRISTOL-MYERS SQUIBB COMPANY 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235891-A1 Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists MTNR1A, MTNR1B, PER2 KDM4E 2851/4885GLA 4670/4885RCE1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.